Fifty years of discovery of alpha-fetoprotein as the first tumor marker

Nikulina, D M; Terentyev, A. A.; Галимзянов, Х М; Jurišić, Vladimir

doi:10.2298/sarh1502100n

Cited by 15 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brief, AFP has a similar molecular structure to albumin and contains one glycoprotein consisting of 591 amino acids. The gene for AFP is localized in chromosome 4 and its expression is elevated in the fetal period of human development as well as in adults with liver disease, including HCC [16]. According to its reactivity to lens culinaris agglutinin (LCA), AFP can be classified as AFP-L1, AFP-L2 and AFP L-3.…”

Section: Proteinsmentioning

confidence: 99%

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Mocan

Simão

Castro

et al. 2020

JCM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for an earlier diagnosis, follow-up or prediction of treatment response, among others. In this regard, the “HCC circulome”, defined as the pool of circulating molecules in the bloodstream derived from the primary tumor, represents an appealing target, the so called liquid biopsy. Such molecules encompass circulating tumor proteins, circulating tumor cells (CTCs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), and circulating tumor nucleic acids, namely circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). In this article, we summarize recent findings highlighting the promising role of liquid biopsies as novel potential biomarkers in HCC, emphasizing on its clinical performance.

show abstract

Section: Proteinsmentioning

confidence: 99%

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Mocan

Simão

Castro

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…The mechanisms underlying the roles of either blood AFP or platelet levels in HCC growth are not entirely clear, but they have been investigated to some extent. Thus AFP, which was first discovered 55 years ago by Tatarinov experimentally and then by Abelev clinically [13], has retained its place in HCC diagnosis and as a marker of response to therapy and for prognosis [14]. However, its mechanism of action in HCC growth and aggressiveness is far from clear.…”

Section: Discussionmentioning

confidence: 99%

“…Regardless, tumor size is still regarded as a key variable in HCC prognosis [36] and was seen to be significant for survival in Table 4, but only in the good-survival three-parameter group. Other parameters are also regarded as important for HCC survival, including serum levels of AFP [7,[12][13][14]23] albumin, and bilirubin [37]. For patients with PVT, the level of MTD made no difference to survival.…”

Section: Discussionmentioning

confidence: 99%

Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs

Carr

Guerra

Donghia

et al. 2021

Cancers

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival. Aim. To examine patterns of tumor factors in large HCC patients. Methods. A database of large HCC patients was examined. Results. A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin >3.5 g/dL and the absence of both PVT and multifocality had the best survival rate, while all combinations that included the presence of PVT had poor survival and hazard ratios. We identified four clinical phenotypes, each with a distinct median survival: patients with or without PVT or multifocality plus serum albumin ≥3.5 (g/dL), with each subgroup displaying high (≥100 IU/mL) or low (<100 IU/mL) blood AFP levels. Across a range of MTDs, we identified only two significant trends, blood AFP and platelets. Conclusions. Patients with large HCCs have distinct phenotypes and survival, as identified by the combination of PVT, multifocality, and blood albumin levels.

show abstract

“…Following the discovery of alpha-fetoprotein (AFP) in HCC by the Russian scientist, screening HCC is widely recommended for patients who are under risk for more than 40 years [7,8] .…”

Section: Introductionmentioning

confidence: 99%

Screening for hepatocellular carcinoma: summary of current guidelines up to 2018

Yılmaz¹,

Yilmaz²,

Süer³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related to worldwide death with a great geographical variation. To be eligible for curative therapy at the time of diagnosis is important. However, the majority of cases are diagnosed at late stages. This can be achieved with applicable screening modalities. Until now, many organizations around the world have developed guidelines according to their own evidence-based data for screening of HCC. The purpose of this article is to review the screening modalities of HCC to assist gastroenterologists and providers involved in the management of HCC.

show abstract

Fifty years of discovery of alpha-fetoprotein as the first tumor marker

Cited by 15 publications

References 15 publications

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs

Screening for hepatocellular carcinoma: summary of current guidelines up to 2018

Contact Info

Product

Resources

About